




Activities of the Tuberculosis Trials Consortium (TBTC)

Working Group on New Drugs Annual Meeting
November 3rd, 2022


Wendy Carr, PhD
Branch Chief
Clinical Research Branch
Division of Tuberculosis Elimination



Tuberculosis Trials Consortium (TBTC)

- “... is a collaboration of researchers from CDC, domestic and international public health programs, academic medical centers, and selected Veterans Administration medical centers, whose mission is to conduct **programmatically relevant** clinical, laboratory, and epidemiologic research concerning the diagnosis, clinical management, and prevention of tuberculosis infection and disease.”


TBTC Trials Enrollment, 1995-2022



Total enrolled **17,688** participants*

TBTC established in 1993, first enrolment in 1995
*As of 12 July 2022

TBTC Trials Enrollment, 1995-2022



Total enrolled **17,688** participants*

TBTC established in 1993, first enrolment in 1995
*As of 12 July 2022

Tuberculosis Trials Consortium (TBTC) for the 2021-2030 cycle



TBTC Sites

United States
Canada
Australia

Haiti
South Africa
Uganda
Vietnam
Benin


AMERICAS		AFRICA																																							
<table border="1"> <thead> <tr> <th>CANADA</th> <th>UNITED STATES</th> </tr> </thead> <tbody> <tr> <td>ALBERTA</td> <td>DENVER, COLORADO</td> </tr> <tr> <td>Edmonton TB Clinic (#99) ★</td> <td>Denver Metro Tuberculosis Clinic (#22)</td> </tr> <tr> <td>Calgary TB Clinic (#51) ★</td> <td>SEATTLE, WASHINGTON</td> </tr> <tr> <td>MONTREAL</td> <td>Seattle & King County - Public Health TB Control Program (#26)</td> </tr> <tr> <td>Respiratory Clinic of McGill University Health Centre (MUHC) (#25) ★</td> <td>MINNEAPOLIS, MINNESOTA</td> </tr> <tr> <td>TORONTO</td> <td>Minneapolis VA Healthcare System and Hennepin County Public Health (#60)</td> </tr> <tr> <td>Toronto Western Hospital (#50) ★</td> <td>NEW YORK, NEW YORK</td> </tr> <tr> <td>VANCOUVER</td> <td>VA New York Harbor Healthcare System and New York City TB Control (#64)</td> </tr> <tr> <td>British Columbia Centre for Disease Control (BCCDC) (#52) ★</td> <td>SAN ANTONIO, TEXAS</td> </tr> <tr> <td>HAITI</td> <td>San Antonio VA Medical Center, Metropolitan Health and University Texas Health San Antonio (#63)</td> </tr> <tr> <td>PORT-AU-PRINCE</td> <td>WASHINGTON, D.C.</td> </tr> <tr> <td>GHESKIO-IMIS (#67)</td> <td>Washington DC VA Medical Center, DC Health and the George Washington University (#53)</td> </tr> <tr> <td>GHESKIO-INLR (#45)</td> <td></td> </tr> </tbody> </table>		CANADA	UNITED STATES	ALBERTA	DENVER, COLORADO	Edmonton TB Clinic (#99) ★	Denver Metro Tuberculosis Clinic (#22)	Calgary TB Clinic (#51) ★	SEATTLE, WASHINGTON	MONTREAL	Seattle & King County - Public Health TB Control Program (#26)	Respiratory Clinic of McGill University Health Centre (MUHC) (#25) ★	MINNEAPOLIS, MINNESOTA	TORONTO	Minneapolis VA Healthcare System and Hennepin County Public Health (#60)	Toronto Western Hospital (#50) ★	NEW YORK, NEW YORK	VANCOUVER	VA New York Harbor Healthcare System and New York City TB Control (#64)	British Columbia Centre for Disease Control (BCCDC) (#52) ★	SAN ANTONIO, TEXAS	HAITI	San Antonio VA Medical Center, Metropolitan Health and University Texas Health San Antonio (#63)	PORT-AU-PRINCE	WASHINGTON, D.C.	GHESKIO-IMIS (#67)	Washington DC VA Medical Center, DC Health and the George Washington University (#53)	GHESKIO-INLR (#45)		<table border="1"> <thead> <tr> <th>BENIN</th> </tr> </thead> <tbody> <tr> <td>COTONOU</td> </tr> <tr> <td>National Referral University Hospital for Pneumo-Physiology (#77) ★</td> </tr> <tr> <td>SOUTH AFRICA</td> </tr> <tr> <td>CAPE TOWN</td> </tr> <tr> <td>Stellenbosch University Partnership with DC VAMC, Desmond Tutu TB Centre, Brooklyn Chest, Kulsrivier, Tambo Road, Khayelitsha and Ikamva at Tygerberg Hospital (#33)</td> </tr> <tr> <td>The Medical University of South Carolina and the University of Cape Town Lung Institute (#9)</td> </tr> <tr> <td>UGANDA</td> </tr> <tr> <td>KAMPALA</td> </tr> <tr> <td>Uganda-Case Western Reserve University Research Collaboration (#30)</td> </tr> </tbody> </table>		BENIN	COTONOU	National Referral University Hospital for Pneumo-Physiology (#77) ★	SOUTH AFRICA	CAPE TOWN	Stellenbosch University Partnership with DC VAMC, Desmond Tutu TB Centre, Brooklyn Chest, Kulsrivier, Tambo Road, Khayelitsha and Ikamva at Tygerberg Hospital (#33)	The Medical University of South Carolina and the University of Cape Town Lung Institute (#9)	UGANDA	KAMPALA	Uganda-Case Western Reserve University Research Collaboration (#30)
CANADA	UNITED STATES																																								
ALBERTA	DENVER, COLORADO																																								
Edmonton TB Clinic (#99) ★	Denver Metro Tuberculosis Clinic (#22)																																								
Calgary TB Clinic (#51) ★	SEATTLE, WASHINGTON																																								
MONTREAL	Seattle & King County - Public Health TB Control Program (#26)																																								
Respiratory Clinic of McGill University Health Centre (MUHC) (#25) ★	MINNEAPOLIS, MINNESOTA																																								
TORONTO	Minneapolis VA Healthcare System and Hennepin County Public Health (#60)																																								
Toronto Western Hospital (#50) ★	NEW YORK, NEW YORK																																								
VANCOUVER	VA New York Harbor Healthcare System and New York City TB Control (#64)																																								
British Columbia Centre for Disease Control (BCCDC) (#52) ★	SAN ANTONIO, TEXAS																																								
HAITI	San Antonio VA Medical Center, Metropolitan Health and University Texas Health San Antonio (#63)																																								
PORT-AU-PRINCE	WASHINGTON, D.C.																																								
GHESKIO-IMIS (#67)	Washington DC VA Medical Center, DC Health and the George Washington University (#53)																																								
GHESKIO-INLR (#45)																																									
BENIN																																									
COTONOU																																									
National Referral University Hospital for Pneumo-Physiology (#77) ★																																									
SOUTH AFRICA																																									
CAPE TOWN																																									
Stellenbosch University Partnership with DC VAMC, Desmond Tutu TB Centre, Brooklyn Chest, Kulsrivier, Tambo Road, Khayelitsha and Ikamva at Tygerberg Hospital (#33)																																									
The Medical University of South Carolina and the University of Cape Town Lung Institute (#9)																																									
UGANDA																																									
KAMPALA																																									
Uganda-Case Western Reserve University Research Collaboration (#30)																																									
<table border="1"> <thead> <tr> <th colspan="2">WESTERN PACIFIC</th> </tr> <tr> <th>AUSTRALIA</th> <th>VIETNAM</th> </tr> </thead> <tbody> <tr> <td>LIVERPOOL</td> <td>CAN THO PROVINCE</td> </tr> <tr> <td>Liverpool Hospital (#73) ★</td> <td>Tho Not District TB Unit (#76) ★</td> </tr> <tr> <td>PARRAMATTA</td> <td>HO CHI MINH CITY</td> </tr> <tr> <td>Parramatta Chest Clinic (#72) ★</td> <td>District 6 TB Unit (#74) ★</td> </tr> <tr> <td>SYDNEY</td> <td>Phol Viet Respiratory Centre (#75) ★</td> </tr> <tr> <td>Royal Prince Alfred Hospital (#71) ★</td> <td></td> </tr> </tbody> </table>		WESTERN PACIFIC		AUSTRALIA	VIETNAM	LIVERPOOL	CAN THO PROVINCE	Liverpool Hospital (#73) ★	Tho Not District TB Unit (#76) ★	PARRAMATTA	HO CHI MINH CITY	Parramatta Chest Clinic (#72) ★	District 6 TB Unit (#74) ★	SYDNEY	Phol Viet Respiratory Centre (#75) ★	Royal Prince Alfred Hospital (#71) ★		<ul style="list-style-type: none"> VENDOR SITES VA MEDICAL CENTER SITES MCGILL/CAB-V NETWORK 																							
WESTERN PACIFIC																																									
AUSTRALIA	VIETNAM																																								
LIVERPOOL	CAN THO PROVINCE																																								
Liverpool Hospital (#73) ★	Tho Not District TB Unit (#76) ★																																								
PARRAMATTA	HO CHI MINH CITY																																								
Parramatta Chest Clinic (#72) ★	District 6 TB Unit (#74) ★																																								
SYDNEY	Phol Viet Respiratory Centre (#75) ★																																								
Royal Prince Alfred Hospital (#71) ★																																									

TBTC Studies: ongoing and in planning

Study	Phase	Topic	Status
S31/A5349	3	4-month daily rifapentine (RPT) regimens for active DS TB	Completed Secondary analyses ongoing
S31PK	Sub-study	Pharmacokinetics (PK)/pharmacodynamics (PD) TB drugs	Analysis
S31PG	Sub-study	Pharmacogenetics and PK, drug response, and safety	Analysis
S31A	Sub-study	MTB RNA transcriptomic expression profiling in sputum	Analysis
S31B	Sub-study	Novel biomarkers to shorten TB treatment	Analysis
S31 Adolescents	Sub-study	Adolescent recruitment, enrollment, and retention	Analysis
S35	1/2	Novel pediatric formulation RPT PK/safety for LTBI	Enrolling
S35A	Sub-study	Acceptability of pediatric formulation RPT	Analysis
S37/ASTERoid	3	6-weeks daily RPT for LTBI	Enrolling
S38/CRUSH-TB	2C	Novel short-course BMZ-based regimens for DS TB	Planning
Radiant Kids	1/2	Pediatric PK, safety, tolerability of RPT-MOX Study 31 regimen	Planning

Study 35: Novel pediatric formulation RPT PK/safety for LTBI

- **Design:** Phase 1/2, single arm, open-label, exposure-controlled dose finding study using an adaptive design
- **Objective:** Evaluate the PK, safety and tolerability of **rifapentine (RPT)** given in a new, water-dispersible fixed dose combination formulation with isoniazid once-weekly, for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years with LTBI
- **Sample size:** 72 participants (4 age cohorts)
- **Status:** Enrolling





Study 37: 6 weeks daily RPT for LTBI (ASTERoid)

- **Design:** Phase 3, randomized, controlled, open-label non-inferiority trial
- **Objective:** Compare the safety – and if safe, compare the effectiveness of daily **rifapentine** for 6 weeks (**6wP**) to a comparator arm for the prevention of TB in persons >12 years old with LTBI
- **Regimens:**
 - 6wP
 - Control (local standard 12-16 week rifamycin-based treatment 3HP, 3HR, or 4R)
- **Sample size:** 3,400 participants
- **Status:** Enrolling

Study 38: Novel short-course BMZ-based regimens for DS TB (CRUSH-TB)

- **Design:** Phase 2C randomized, open-label adaptive trial, 3+ arms
- **Objective:** Assess safety and efficacy of 4-month **bedaquiline, moxifloxacin, pyrazinamide (BMZ)**-based regimens compared to 6-month standard of care among adult and adolescent patients with drug-susceptible pulmonary TB
- **Regimens:**
 - 2BMZRb/2BMRb
 - 2BMZD/2BMD
 - Control (2HRZE/4HR)
- **Sample size:** 288 participants
- **Status:** Nearing Implementation





For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

